Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 7707 Fannin St., Suite 140 HOUSTON TX 77054 |
Tel: | N/A |
Website: | https://kiromic.com |
IR: | See website |
Key People | ||
Pietro Bersani Interim Chief Executive Officer, Director | Brian Hungerford Interim Chief Financial Officer and Principal Accounting | Leonardo Mirandola Interim Chief Operating Officer, Chief Scientific Officer | Scott Dahlbeck Chief of Staff |
Business Overview |
Kiromic BioPharma, Inc. is a clinical-stage fully integrated biotherapeutics company using its DIAMOND artificial intelligence (AI) 2.0 target discovery engine to develop and commercialize cell therapies focusing on immuno-oncology. The Company is developing multi-indication allogeneic T cell therapies that exploit the natural potency of Gamma Delta T cells (GDTs) to target solid tumors. It has three product candidates: Deltacel non-engineered GDTs, expanded and activated with technology, Procel GDTs engineered with a PD-1 switch receptor and Isocel GDTs engineered with an anti-Mesothelin isoform 2 Chimeric Antigen Receptor. Its Procel and Isocel product candidates consist of allogeneic, engineered, off-the-shelf GDT cells and they are in the preclinical development stage. Its Deltacel product candidate consists of non-engineered GDTs used to treat solid tumors. It also has new technologies in development to support its end-to-end approach. |
Financial Overview |
For the nine months ended 30 September 2023, Kiromic Biopharma Inc revenues was not reported. Net loss applicable to common stockholders decreased 36% to $17.8M. Lower net loss reflects General and administrative - Balanci decrease of 42% to $7.7M (expense), Research and development - Balan decrease of 38% to $6.5M (expense), Other income increase from $0K to $1.8M (income). |
Employees: | 31 as of Dec 31, 2022 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $8.68M as of Sep 30, 2023 |
Annual revenue (TTM): | $0.00M as of Sep 30, 2023 |
EBITDA (TTM): | -$19.32M as of Sep 30, 2023 |
Net annual income (TTM): | -$24.99M as of Sep 30, 2023 |
Free cash flow (TTM): | -$20.08M as of Sep 30, 2023 |
Net Debt Last Fiscal Year: | $5.28M as of Sep 30, 2023 |
Shares outstanding: | 1,288,235 as of Mar 18, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |